Efficacy and safety of the H1N1 monovalent vaccine in renal-transplant recipients and dialysis patients

Abstract

Background: The (H1N1)v influenza virus infection emerged in 2009 as a serious disease in targeted populations. Herein, we report on the tolerability and efficacy of (anti-H1N1)v vaccination in dialysis and transplant patients. Results: Seroprotection rate after vaccination was greater in dialysis patients (DPs) than renal-transplant recipients (RTRs) (p = 0.007), as was seroconversion (p = 0.001). Serologic response was similar in PDPs and HDPs. Methods: 18 renal-transplant recipients (RTR) and 19 dialysis patients (DP) (12 patients treated with peritoneal dialysis (PDP), 7 patients treated with hemodialysis (HDP)) were enrolled. DPs received one monovalent H1N1 adjuvantedvaccine injection, and RTRs received two unadjuvanted vaccine injections within a 21-d period. Serologic response was defined as a haemagglutination inhibition titer of ≥40 (seroprotection) and/or at least a 4-fold increase in antibody titer from baseline (seroconversion). Conclusions: Serologic response was satisfactory in DPs, whichever dialysis mode (DPD or HDP). It was low in RTRs as compared with DPs. © 2011 Landes Bioscience.